Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.36 +0.01 (+0.02%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Akero Therapeutics Announces Proposed Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
These stocks are moving in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Dow Edges Higher; AT&T Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Stocks Fall Sharply Alongside Tech; VIX Soars ↗
Stocks are lower today amid a global tech selloff. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dada Nexus, Titan Machinery, AT&T And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant ↗
The analyst highlighted that major pharmaceutical companies are already pursuing GLP-1-based therapies for MASH, but he believes efruxifermin could complement these treatments. 
Via Stocktwits
News headline image
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December ↗
 
Via Benzinga
Topics Economy
News headline image
These stocks that are showing activity before the opening bell on Monday. ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study ↗
The companies are both working on treatments for a liver disease known as MASH. 
Via Investor's Business Daily
News headline image
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why ↗
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver fibrosis and safety. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.